According to a new report published by Allied Market Research, titled, "Bronchodilators Market by Drug Class, Indication and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018–2026," the global bronchodilators market size is expected to reach $41,487.53 million by 2026, registering a CAGR of 5.2% from 2019 to 2026, in terms of value. Bronchodilators are usually recommended as first‐line treatment for diseases in people with respiratory disorders. Bronchodilators are drugs that relax muscles that tighten around the airways. These drugs open airways and allow more air to move in and out of lungs. They are also used to reduce mucus from lungs. Patients suffering from respiratory disorders consume these drugs through the help of nebulizers or inhalers. In addition, inhaler bronchodilators have effects on mucociliary clearance as well. Bronchodilators are used in the treatment of obstructive lung diseases by relaxing the lung muscles and widening the airways (bronchi). They are used in the treatment of asthma and chronic obstructive pulmonary diseases (COPD).

Albuterol (brand names Ventolin and Proventalin); Xopenex (levalbuterol); and Combivent, a combination of ipratropium bromide and albuterol, are bronchodilators used to treat bronchospasms caused due to cystic fibrosis. These are being widely used by patients as they suffer from difficulty in breathing due to mucus accumulation.

Significant increase in prevalence of cystic fibrosis, asthma, and other disorders across the globe is the major factor driving the bronchodilators market growth. Furthermore, other major factors driving the market growth are rise in concern regarding respiratory diseases, such as asthma and sympathomimetics and surge in incidences of respiratory diseases caused due to cigarette smoking. The bronchodilators market is anticipated to grow due to increase in healthcare expenditure, growth in use of homecare devices in the healthcare industry, and rapid adoption of advanced medical solutions. Presently, most healthcare practitioners and pulmonary diseases specialists prefer combination of a drug and a device, owing to its fast and effective outcome. However, the factors such as high cost associated with bronchodilators and side effects caused due to their excessive use hampers the bronchodilators market growth.

By indication, the asthma segment accounted for majority of the bronchodilators market share in 2018 and is expected to exhibit a prominent growth rate in the future. This is attributed to significant surge in the prevalence of asthma across the globe. For instance, according to the Asthma and Allergy Foundation of America, asthma accounts for 9.8 million hospital visits, 188,968 discharges from hospital inpatient care, and 1.8 million emergency department visits each year.

By drug type, the anticholinergics segment dominated the bronchodilators market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the fact that anticholinergics are available in both long acting and short acting forms.

Key Findings of the Study:

• By indication, the asthma segment accounted for the highest market share of 28% in 2018, and is anticipated to grow at the fastest rate during the forecast period.
• By region, North America was the major shareholder and accounted for the highest share of 45% in 2018.
• By drug Type, the combination drugs segment is expected to grow at a CAGR of 5.4% during the forecast period.
• By route of administration, the inhaler segment dominated the market in 2018, and is anticipated to maintain its dominance during the forecast period.

Comprehensive competitive analysis and profiles of major market players such as AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vectura Group plc and Abbott Laboratories. are provided in this report.